Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that is mainly employed to treat mild-to-moderate pain & reduces pain, inflammation, swelling, and stiffness. This drug is applicable for inflammatory disorders such as arthritis, rheumatoid arthritis, dermatomyositis, osteoarthritis, dental pain, spondylarthritis, and gout attacks.
Portland, OR -- (SBWIRE) -- 09/15/2017 -- The major factors that contribute to the growth of the Diclofenac Market include increasing prevalence of autoimmune and respiratory conditions such as arthritis & dental pain, increasing adoption of anti-inflammatory drugs, growing awareness about anti-inflammatory therapeutics, development in R&D activities, and attractive government initiatives in emerging countries.
However, side effects of anti-inflammatory drugs and patent expiry issues of drugs may impede the market growth. High demand for better and novel anti-inflammatory therapeutics with lesser side effects & better efficacy are expected to provide numerous opportunities for market growth during the forecast period.
Get PDF Brochure of this report: https://www.alliedmarketresearch.com/request-toc-and-sample/3809
The diclofenac market is segmented on the basis of indication, route of administration, and region. According to indication, the market is divided into osteoarthritis, ankylosing spondylitis, dysmenorrhea, rheumatoid arthritis, migraine, pain, and others. On the basis of formulation, the market is segmented into oral and parenteral. Geographically, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players that operate in this market include Auro Laboratories Limited, Henan Dongtai Pharmaceutical Co., Bayer AG, Pfizer Inc., Hunan Warrant Pharmaceutical Co., Ltd, Novartis AG, XianShi Pharmaceutical Group, Merck & Co., Inc., Istituto Biochimico Italiano G. Lorenzini S.p.A., and Dezhou Deyao Pharmaceutical Co., Ltd.
Diclofenac Market Key Segments:
- Ankylosing Spondylitis
- Rheumatoid Arthritis
By Route of Administration
Early buyers will receive 20% customization on this report